Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00735436 · ClinicalTrials.gov registry record · Phase 2
A Study of Gliadel Followed by Avastin + Irinotecan for Glioblastoma Multiforme (GBM)
A Phase 2 study, sponsored by Duke University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 18
- Enrollment target
NCT00735436 is a Phase 2 study that was terminated before completion, run by Duke University. The registered enrollment target is 18 participants.
The verdict
NCT00735436, a Phase 2 study, was terminated before completion, sponsored by Duke University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 18 participants
- Enrollment target
Study Summary
The primary objective of the study is to use 24 week survival to assess the efficacy of the combination of Gliadel followed by Avastin and irinotecan in the treatment of grade IV malignant glioma patients following surgical resection. The secondary objectives are to determine the progression-free survival following the combination of Gliadel followed by Avastin and irinotecan and to describe the toxicity of Gliadel followed by Avastin and irinotecan.
Interventions
- DRUG Gliadel/Avastin/CPT-11
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2008-12 |
| Est. Completion | 2012-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00735436
The ClinicalTrials.gov registry entry for NCT00735436 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Gliadel/Avastin/CPT-11 is the first listed.
NCT00735436 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00735436 about?
NCT00735436 is a clinical study titled "A Study of Gliadel Followed by Avastin + Irinotecan for Glioblastoma Multiforme (GBM)". The primary objective of the study is to use 24 week survival to assess the efficacy of the combination of Gliadel followed by Avastin and irinotecan in the treatment of grade IV malignant glioma patients following surgical resection. The secondary objectives are to determine the progression-free su...
What is the current status of trial NCT00735436?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2008-12. Estimated completion is 2012-10.
What interventions are being tested in trial NCT00735436?
The interventions under investigation include: Gliadel/Avastin/CPT-11 (DRUG).
Who is sponsoring clinical trial NCT00735436?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.